• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于定量质谱的蛋白质组学分析在前列腺癌精准医学中的应用

Quantitative Mass Spectrometry-Based Proteomic Profiling for Precision Medicine in Prostate Cancer.

作者信息

Flores-Morales Amilcar, Iglesias-Gato Diego

机构信息

Faculty of Health and Medical Sciences, Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.

Danish Cancer Society Research Center, Danish Cancer Society, Copenhagen, Denmark.

出版信息

Front Oncol. 2017 Nov 7;7:267. doi: 10.3389/fonc.2017.00267. eCollection 2017.

DOI:10.3389/fonc.2017.00267
PMID:29164064
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5674010/
Abstract

Prostate cancer (PCa) is one of the most frequently diagnosed cancer among men in the western societies. Many PCa patients bear tumors that will not threat their lives if left untreated or if treatment is delayed. Our inability for early identification of these patients has resulted in massive overtreatment. Therefore, there is a great need of finding biomarkers for patient stratification according to prognostic risk; as well as there is a need for novel targets that can allow the development of effective treatments for patients that progress to castration-resistant PCa. Most biomarkers in cancer are proteins, including the widely-used prostate-specific antigen (PSA). Recent developments in mass spectrometry allow the identification and quantification of thousands of proteins and posttranslational modifications from small amounts of biological material, including formalin-fixed paraffin-embedded tissues, and biological fluids. Novel diagnostic and prognostic biomarkers have been identified in tissue, blood, urine, and seminal plasma of PCa patients, and new insights in the ethology and progression of this disease have been achieved using this technology. In this review, we summarize these findings and discuss the potential of this technology to pave the way toward the clinical implementation of precision medicine in PCa.

摘要

前列腺癌(PCa)是西方社会男性中最常被诊断出的癌症之一。许多前列腺癌患者所患的肿瘤如果不治疗或治疗延迟,不会威胁到他们的生命。我们无法早期识别这些患者导致了大量的过度治疗。因此,迫切需要找到根据预后风险对患者进行分层的生物标志物;同时也需要新的靶点,以便能够为进展为去势抵抗性前列腺癌的患者开发有效的治疗方法。癌症中的大多数生物标志物都是蛋白质,包括广泛使用的前列腺特异性抗原(PSA)。质谱技术的最新进展使得能够从少量生物材料(包括福尔马林固定石蜡包埋组织和生物体液)中鉴定和定量数千种蛋白质及翻译后修饰。在前列腺癌患者的组织、血液、尿液和精浆中已经鉴定出了新的诊断和预后生物标志物,并且利用这项技术在该疾病的病因学和进展方面取得了新的见解。在这篇综述中,我们总结了这些发现,并讨论了这项技术为前列腺癌精准医学的临床应用铺平道路的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3703/5674010/b3f91311e5da/fonc-07-00267-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3703/5674010/b3f91311e5da/fonc-07-00267-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3703/5674010/b3f91311e5da/fonc-07-00267-g001.jpg

相似文献

1
Quantitative Mass Spectrometry-Based Proteomic Profiling for Precision Medicine in Prostate Cancer.基于定量质谱的蛋白质组学分析在前列腺癌精准医学中的应用
Front Oncol. 2017 Nov 7;7:267. doi: 10.3389/fonc.2017.00267. eCollection 2017.
2
The Proteome of Primary Prostate Cancer.原发性前列腺癌的蛋白质组。
Eur Urol. 2016 May;69(5):942-52. doi: 10.1016/j.eururo.2015.10.053. Epub 2015 Dec 2.
3
Proteomics in diagnosis of prostate cancer.蛋白质组学在前列腺癌诊断中的应用
Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2015;36(1):5-36.
4
High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification.高通量蛋白质组学分析 FFPE 组织样本有助于肿瘤分层。
Mol Oncol. 2019 Nov;13(11):2305-2328. doi: 10.1002/1878-0261.12570. Epub 2019 Sep 18.
5
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
6
The role of proteomics in prostate cancer research: biomarker discovery and validation.蛋白质组学在前列腺癌研究中的作用:生物标志物的发现和验证。
Clin Biochem. 2013 Apr;46(6):524-38. doi: 10.1016/j.clinbiochem.2012.12.012. Epub 2012 Dec 22.
7
Recent progress in urinary proteome analysis for prostate cancer diagnosis and management.用于前列腺癌诊断和管理的尿液蛋白质组分析的最新进展。
Expert Rev Mol Diagn. 2015;15(12):1539-54. doi: 10.1586/14737159.2015.1104248. Epub 2015 Oct 22.
8
Multiplexed quantitative proteomics in prostate cancer biomarker development.前列腺癌生物标志物开发中的多重定量蛋白质组学。
Adv Cancer Res. 2024;161:31-69. doi: 10.1016/bs.acr.2024.04.003. Epub 2024 Apr 25.
9
miRNA in Prostate Cancer: New Prospects for Old Challenges.前列腺癌中的微小RNA:旧挑战的新前景
EJIFCC. 2014 Apr 28;25(1):79-98. eCollection 2014 Apr.
10
Proteomic Analysis of Prostate Cancer FFPE Samples Reveals Markers of Disease Progression and Aggressiveness.前列腺癌福尔马林固定石蜡包埋样本的蛋白质组学分析揭示疾病进展和侵袭性的标志物。
Cancers (Basel). 2022 Aug 2;14(15):3765. doi: 10.3390/cancers14153765.

引用本文的文献

1
Complementary analysis of proteome-wide proteomics reveals changes in RNA binding protein-profiles during prostate cancer progression.全蛋白质组学的互补分析揭示了前列腺癌进展过程中 RNA 结合蛋白谱的变化。
Cancer Rep (Hoboken). 2023 Oct;6(10):e1886. doi: 10.1002/cnr2.1886. Epub 2023 Aug 17.
2
Bile Acids: Physiological Activity and Perspectives of Using in Clinical and Laboratory Diagnostics.胆汁酸:生理活性及在临床与实验室诊断中的应用展望。
Molecules. 2022 Nov 13;27(22):7830. doi: 10.3390/molecules27227830.
3
Proteomic Landscape of Prostate Cancer: The View Provided by Quantitative Proteomics, Integrative Analyses, and Protein Interactomes.

本文引用的文献

1
Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer.用于晚期转移性癌症个性化治疗决策支持的细胞外囊泡及其对前列腺癌的潜在影响。
Prostate. 2017 Oct;77(14):1416-1423. doi: 10.1002/pros.23403. Epub 2017 Aug 29.
2
Integrative Clinical Genomics of Advanced Prostate Cancer.晚期前列腺癌的综合临床基因组学
Cell. 2015 Jul 16;162(2):454. doi: 10.1016/j.cell.2015.06.053.
3
Optimization and Modeling of Quadrupole Orbitrap Parameters for Sensitive Analysis toward Single-Cell Proteomics.
前列腺癌的蛋白质组全景:定量蛋白质组学、综合分析和蛋白质相互作用组所呈现的视角
Cancers (Basel). 2021 Sep 27;13(19):4829. doi: 10.3390/cancers13194829.
4
Diagnostic and prognostic potential of the proteomic profiling of serum-derived extracellular vesicles in prostate cancer.血清衍生细胞外囊泡的蛋白质组学分析在前列腺癌中的诊断和预后潜力。
Cell Death Dis. 2021 Jun 21;12(7):636. doi: 10.1038/s41419-021-03909-z.
5
Theranostics in Boron Neutron Capture Therapy.硼中子俘获治疗中的诊疗一体化
Life (Basel). 2021 Apr 10;11(4):330. doi: 10.3390/life11040330.
6
Mass spectrometry-based tear proteomics for noninvasive biomarker discovery.基于质谱的泪液蛋白质组学用于非侵入性生物标志物发现。
Mass Spectrom Rev. 2022 Sep;41(5):842-860. doi: 10.1002/mas.21691. Epub 2021 Mar 24.
7
Alterations in seminal plasma proteomic profile in men with primary and secondary infertility.精液血浆蛋白质组谱改变与原发性和继发性不育男性。
Sci Rep. 2020 May 5;10(1):7539. doi: 10.1038/s41598-020-64434-1.
8
Characterization of HMGB1/2 Interactome in Prostate Cancer by Yeast Two Hybrid Approach: Potential Pathobiological Implications.利用酵母双杂交方法对前列腺癌中HMGB1/2相互作用组的表征:潜在的病理生物学意义
Cancers (Basel). 2019 Nov 5;11(11):1729. doi: 10.3390/cancers11111729.
9
Clinical significance of serum PSA in breast cancer patients.乳腺癌患者血清 PSA 的临床意义。
BMC Cancer. 2019 Oct 29;19(1):1021. doi: 10.1186/s12885-019-6256-2.
10
Absolute Quantification of Apolipoproteins Following Treatment with Omega-3 Carboxylic Acids and Fenofibrate Using a High Precision Stable Isotope-labeled Recombinant Protein Fragments Based SRM Assay.使用基于高精密稳定同位素标记重组蛋白片段的 SRM 分析方法对 ω-3 羧酸和非诺贝特治疗后的载脂蛋白进行绝对定量。
Mol Cell Proteomics. 2019 Dec;18(12):2433-2446. doi: 10.1074/mcp.RA119.001765. Epub 2019 Oct 7.
优化和四极杆轨道阱参数建模以实现单细胞蛋白质组学的灵敏分析。
J Proteome Res. 2017 Oct 6;16(10):3711-3721. doi: 10.1021/acs.jproteome.7b00416. Epub 2017 Sep 1.
4
Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics.使用基于质谱的靶向蛋白质组学技术定量检测前列腺癌中的突变 SPOP 蛋白。
J Transl Med. 2017 Aug 15;15(1):175. doi: 10.1186/s12967-017-1276-7.
5
Quantitative, multiplexed workflow for deep analysis of human blood plasma and biomarker discovery by mass spectrometry.用于通过质谱对人血浆进行深度分析和生物标志物发现的定量、多重工作流程。
Nat Protoc. 2017 Aug;12(8):1683-1701. doi: 10.1038/nprot.2017.054. Epub 2017 Jul 27.
6
A comprehensive analysis and annotation of human normal urinary proteome.全面分析和注释人类正常尿蛋白质组。
Sci Rep. 2017 Jun 8;7(1):3024. doi: 10.1038/s41598-017-03226-6.
7
Active Surveillance for Prostate Cancer: How to Do It Right.前列腺癌的主动监测:如何正确实施
Oncology (Williston Park). 2017 May 15;31(5):333-40, 345.
8
Methods, Tools and Current Perspectives in Proteogenomics.蛋白质基因组学中的方法、工具及当前观点
Mol Cell Proteomics. 2017 Jun;16(6):959-981. doi: 10.1074/mcp.MR117.000024. Epub 2017 Apr 29.
9
Proteomic analysis of urinary extracellular vesicles from high Gleason score prostate cancer.高 Gleason 评分前列腺癌患者尿细胞外囊泡的蛋白质组学分析。
Sci Rep. 2017 Feb 17;7:42961. doi: 10.1038/srep42961.
10
Genomic hallmarks of localized, non-indolent prostate cancer.局限性、非惰性前列腺癌的基因组特征。
Nature. 2017 Jan 19;541(7637):359-364. doi: 10.1038/nature20788. Epub 2017 Jan 9.